GFH276 for people with ras-mutant solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called GFH276 that targets tumors with a RAS mutation. It aims to see if the drug can shrink or slow these tumors. If you have a solid tumor with this mutation, you may be eligible to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You need to be in generally good health, able to care for yourself, and have an expected survival of at least 3 months.
- Your tumor must have a RAS mutation (a specific genetic change).
- You must not have had a PAN-RAS inhibitor before.
- You must not have active brain metastases or severe heart problems.
- You must not have active hepatitis B or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
This trial tests a new targeted pill (GFH375) alone or with another drug for people with a specific gene change (KRAS G12D) in advanced lung cancer. It aims to shrink or slow the cancer, possibly better than current standard treatments.
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new oral drug, GFH276, in people with advanced lung cancer that has a change in a gene called RAS. The drug is designed to target cancers with this specific mutation, and the study aims to find out if it is safe and effective for patients who have not had prior treatment for their advanced disease.
This trial tests a new oral medication (GFH375) for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the drug can shrink tumors or slow cancer growth.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.